DAFNA Capital Management LLC Has $937,000 Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

DAFNA Capital Management LLC cut its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 40.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 88,790 shares of the company's stock after selling 59,504 shares during the quarter. DAFNA Capital Management LLC owned about 0.09% of ARS Pharmaceuticals worth $937,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. KLP Kapitalforvaltning AS acquired a new position in shares of ARS Pharmaceuticals in the fourth quarter worth about $73,000. BNP Paribas Financial Markets acquired a new stake in ARS Pharmaceuticals in the 4th quarter valued at about $75,000. Compass Capital Corp MA ADV acquired a new stake in shares of ARS Pharmaceuticals in the 4th quarter worth $106,000. Teacher Retirement System of Texas acquired a new stake in shares of ARS Pharmaceuticals in the 4th quarter worth $122,000. Finally, Freestone Grove Partners LP purchased a new stake in shares of ARS Pharmaceuticals in the 4th quarter valued at approximately $132,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at ARS Pharmaceuticals

In related news, insider Eric Karas sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the sale, the insider now owns 7,696 shares in the company, valued at approximately $107,744. This represents a 56.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Laura Shawver sold 50,002 shares of the stock in a transaction on Monday, April 7th. The stock was sold at an average price of $12.30, for a total value of $615,024.60. Following the sale, the director now owns 210,346 shares of the company's stock, valued at approximately $2,587,255.80. This represents a 19.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 109,602 shares of company stock valued at $1,311,041 in the last three months. 40.10% of the stock is currently owned by corporate insiders.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ:SPRY traded up $0.07 on Tuesday, hitting $13.36. The company's stock had a trading volume of 817,696 shares, compared to its average volume of 1,197,610. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -26.20 and a beta of 0.84. ARS Pharmaceuticals, Inc. has a 12 month low of $7.55 and a 12 month high of $18.51. The stock's 50-day moving average is $13.20 and its two-hundred day moving average is $12.92.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.56. The company had revenue of $86.58 million during the quarter, compared to the consensus estimate of $15.46 million. Equities analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SPRY. Scotiabank began coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price objective for the company. William Blair restated an "outperform" rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Leerink Partners lifted their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. Raymond James lifted their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a "strong-buy" rating in a research report on Tuesday, January 14th. Finally, Oppenheimer started coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They set an "outperform" rating and a $40.00 target price for the company. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, ARS Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $31.00.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.